Goal of the analysis:
Identify discrepancies between existing clinical data and the evidence required to support a medical device’s safety and efficacy claims. Determine what additional studies, analyses, or data are necessary to fulfill regulatory, payer, and market expectations.
Data required:
- Current clinical study reports (including protocols, endpoints, and statistical methods)
- Post-market surveillance findings, complaint logs, and adverse event data
- Literature reviews and meta-analyses relevant to the device’s therapeutic area
- Benchmarks or comparative data from similar or competing devices
- Regulatory guidelines defining minimum clinical evidence thresholds for device approval or reimbursement
- Internal risk assessments (for example, risk management files, FMEAs)
Detailed step-by-step instruction on how to conduct the analysis:
- Collect and categorize existing evidence. Gather all clinical research reports, real-world data, and post-market surveillance information. Sort them by study type, quality, and relevance to the device’s intended use.
- Compare evidence against regulatory and market requirements. Review agency guidelines (for example, FDA, EU MDR) and payer policies to pinpoint required endpoints, sample sizes, and study designs.
- Assess study design and methodology. Determine if the clinical studies conducted thus far meet accepted standards (for example, randomized controlled trials) and whether their endpoints align with current expectations.
- Evaluate data robustness and quality. Check for statistical significance, consistency of results, and potential biases in the collected data. Identify any limitations in scope or duration of follow-up.
- Identify unmet evidence needs. Document any clinical endpoints, populations, or safety evaluations not sufficiently covered by existing data.
- Rank gaps by priority and impact. Determine which gaps are critical for regulatory approval, market access, or competitive differentiation, and which can be addressed post-launch.
- Compile a remediation plan. Outline recommended actions, such as additional trials, retrospective analyses, or real-world evidence initiatives, to address high-priority data deficiencies.
Format of the output of analysis:
- A written gap analysis report detailing current evidence versus requirements
- A table or matrix mapping each requirement/endpoint to the available data and noting areas of shortfall
- A ranked action plan highlighting recommended studies or supplemental analyses
- An executive summary that outlines key findings, potential risks, and timelines for closing gaps
How to interpret results:
- Minimal gaps in critical areas (for example, safety endpoints, primary efficacy measures) indicate strong alignment with regulatory and market expectations.
- Significant or multiple gaps may delay product approvals or limit market adoption until deficiencies are addressed.
- Persistent gaps in key effectiveness measures or high-risk subpopulations may require substantial additional research efforts.
Steps a company can take to improve on this measure:
- Engage with regulatory bodies early to clarify evidence expectations and reduce the risk of misaligned study designs.
- Conduct strategic literature reviews and meta-analyses to fill minor evidence gaps and build a stronger case.
- Leverage real-world data and post-market surveillance programs to supplement or strengthen existing clinical findings.
- Allocate resources to well-designed clinical trials that focus on high-priority endpoints and underserved patient populations.
- Implement ongoing, iterative reviews of clinical evidence to proactively identify and address future gaps.
